作者: S. Antinori , L. Schifanella , M. Corbellino
DOI: 10.1007/S10096-011-1276-0
关键词: Immunology 、 Biology 、 Cutaneous leishmaniasis 、 Miltefosine 、 Paromomycin 、 Visceral leishmaniasis 、 Leishmania 、 Disease 、 Leishmaniasis 、 Medical microbiology
摘要: Leishmaniases are a clinically heterogeneous group of diseases caused by protozoa the genus Leishmania. There is growing evidence that true incidence disease underestimated, especially in hyperendemic regions. Moreover, climate changes together with increasing movement humans and animals raise concerns about possible introduction Leishmania infection previously spared areas. The emerging immunocompromised patients undergoing bone marrow or solid organ transplantation treatment biologic drugs. Furthermore, deployment military troops travel to endemic areas associated observation number cutaneous disease. Improvement diagnostic methods, both field specialized laboratories, has been obtained through implementation molecular amplification methods using rK39 antigen as substrate. Finally, new therapeutic approaches gaining attention, such use miltefosine for leishmaniasis paromomycin visceral leishmaniasis, well various antileishmanial drugs combination.